Section Arrow
Quote
ADCT.NYSE
- ADC Therapeutics SA
Quotes are at least 15-min delayed:2026/04/08 02:04 EDT
Regular Hours
Last
 3.72
+0.05 (+1.36%)
Day High 
3.78 
Prev. Close
3.67 
1-M High
4.98 
Volume 
800.57K 
Bid
3.43
Ask
4.75
Day Low
3.46 
Open
3.65 
1-M Low
3.56 
Market Cap 
454.63M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.83 
20-SMA 4.04 
50-SMA 4.02 
52-W High 4.98 
52-W Low 1.13 
Exchange NYSE 
Valuation Estimation
EPS (Current/Estimated)
-1.12/-0.63
Enterprise Value
568.11M
Balance Sheet
Book Value Per Share
-1.46
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
81.36M
Operating Revenue Per Share
0.99
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
QNCXQuince Therapeutics0.163+0.0755+86.29%-- 
SILOSilo Pharma0.5302+0.1744+49.02%-- 
LNAILunai Bioworks Inc.0.3941+0.1121+39.75%-- 
CUECue Biopharma0.1882+0.0112+6.33%-- 
TERNTerns Pharmaceuticals52.62-0.16-0.30%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more linesof systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.